These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 12641624

  • 1. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
    Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK.
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL, Rodríguez Rodríguez JR, Borrego Dorado I, Navarro González E, Tirado Hospital JL, Vázquez Albertino R.
    Rev Esp Med Nucl; 2007 Apr; 26(3):138-45. PubMed ID: 17524307
    [Abstract] [Full Text] [Related]

  • 4. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF, Oei HY, Hennemann G, Krenning EP.
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
    Siddiqi A, Foley RR, Britton KE, Sibtain A, Plowman PN, Grossman AB, Monson JP, Besser GM.
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
    [Abstract] [Full Text] [Related]

  • 8. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS, Mohamed G, Al Shammary A, Aldasouqi S, Abdal Salam S, Shoukri M.
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [Abstract] [Full Text] [Related]

  • 12. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
    Chao M.
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
    Zakani A, Saghari M, Eftekhari M, Fard-Esfahani A, Fallahi B, Esmaili J, Assadi M.
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
    [Abstract] [Full Text] [Related]

  • 15. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA, Padovani RP, Biscolla RP, Ikejiri ES, Marchetti RR, Castiglioni ML, Matsumura LK, Maciel RM, Furlanetto RP.
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [Abstract] [Full Text] [Related]

  • 16. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M, Perotti G, Rufini V, Maussier ML, Dottorini M.
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [Abstract] [Full Text] [Related]

  • 17. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
    Oyen WJ, Verhagen C, Saris E, van den Broek WJ, Pieters GF, Corsten FH.
    J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
    [Abstract] [Full Text] [Related]

  • 18. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma.
    Brendel AJ, Lambert B, Guyot M, Jeandot R, Dubourg H, Roger P, Wynchauk S, Manciet G, Lefort G.
    Eur J Nucl Med; 1990 Apr; 16(1):35-8. PubMed ID: 2307172
    [Abstract] [Full Text] [Related]

  • 19. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
    Ma C, Xie J, Kuang A.
    J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
    [Abstract] [Full Text] [Related]

  • 20. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
    Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB, Shong YK.
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.